Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 2, 2012, Pages 296-305

  Zheng, Shuhui ^a   Huang, Jinghe ^a   Zhou, Kewen ^a   Xiang, Qiuling ^a   Zhang, Yaxing ^a   Tan, Zhi ^a   Simoncini, Tommaso ^b   Fu, Xiaodong ^a   Wang, Tinghuai ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Actin cytoskeleton; Cell movement; Focal adhesion kinase; Progesterone; Vascular endothelial cells

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AMIDE; ANDROSTANE DERIVATIVE; CSK TYROSINE PROTEIN KINASE; CSK TYROSINE-PROTEIN KINASE; ESTRANE DERIVATIVE; FOCAL ADHESION KINASE; FURAN DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RHO KINASE; SMALL INTERFERING RNA; WORTMANNIN;

ARTICLE; CELL CULTURE; CELL MOTION; DRUG ANTAGONISM; ENDOTHELIUM CELL; FOCAL ADHESION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

AMIDES; ANDROSTADIENES; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; ESTRENES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; FOCAL ADHESIONS; FURANS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROGESTERONE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; RECEPTORS, PROGESTERONE; RHO-ASSOCIATED KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84863075443     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01305.x     Document Type: Article

References (58)

1. Virdis A, Ghiadoni L, Giannarelli C, et al Endothelial dysfunction and vascular disease in later life. Maturitas. 2010; 67: 20-4.
2. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder. Am J Physiol Heart Circ Physiol. 2006; 291: H985-1002.
3. Herrington DM, Espeland MA, Crouse JR, et al Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 2001; 21: 1955-61.
4. Kublickiene K, Svedas E, Landgren BM, et al Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab. 2005; 90: 6113-22.
5. Majmudar NG, Robson SC, Ford GA. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab. 2000; 85: 1577-83.
6. Angerer P, Stork S, Kothny W, et al Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 2001; 21: 262-8.
7. Hulley S, Grady D, Bush T, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605-13.
8. Viscoli CM, Brass LM, Kernan WN, et al A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001; 345: 1243-9.
9. Hulley S, Furberg C, Barrett-Connor E, et al Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 58-66.
10. Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
11. Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? Int J Cardiol. 2003; 87: 1-8.
12. Kublickiene K, Fu XD, Svedas E, et al Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab. 2008; 93: 1874-83.
13. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005; 308: 1583-7.
14. Fu XD, Flamini M, Sanchez AM, et al Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod. 2008; 14: 225-34.
15. van Nimwegen MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol. 2007; 73: 597-609.
16. Rovin JD, Frierson HF, Ledinh W, et al Expression of focal adhesion kinase in normal and pathologic human prostate tissues. Prostate. 2002; 53: 124-32.
17. Lim ST, Chen XL, Tomar A, et al Knockin mutation reveals an essential role for focal adhesion kinase (FAK) activity in blood vessel morphogenesis, cell motility-polarity, but not cell proliferation. J Biol Chem. 2010; 285: 21526-36.
18. Fu XD, Goglia L, Sanchez AM, et al Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. Endocr Relat Cancer. 2010; 17: 431-43.
19. Simoncini T, Scorticati C, Mannella P, et al Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol. 2006; 20: 1756-71.
20. Grem JL, Geoffroy F, Politi PM, et al Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells. Mol Pharmacol. 1995; 48: 305-15.
21. Rousell RH, Hewett AJ, McEwen J, et al Determination of serum progesterone levels using a direct 125I-radioimmunoassay. Ric Clin Lab. 1979; 9: 185-95.
22. Vadali K, Cai X, Schaller MD. Focal adhesion kinase: an essential kinase in the regulation of cardiovascular functions. IUBMB Life. 2007; 59: 709-16.
23. Fu XD, Simoncini T. Non-genomic sex steroid actions in the vascular system. Semin Reprod Med. 2007; 25: 178-86.
24. Boonyaratanakornkit V, Scott MP, Ribon V, et al Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001; 8: 269-80.
25. Koga F, Xu W, Karpova TS, et al Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci USA. 2006; 103: 11318-22.
26. Roskoski R Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun. 2004; 324: 1155-64.
27. Torsoni AS, Marin TM, Velloso LA, et al RhoA/ROCK signaling is critical to FAK activation by cyclic stretch in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2005; 289: H1488-96.
28. Fu XD, Giretti MS, Baldacci C, et al Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE. 2008; 3: e2790.
29. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell. 2000; 92: 305-16.
30. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005; 96: 379-86.
31. Braren R, Hu H, Kim YH, et al Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol. 2006; 172: 151-62.
32. Chien S, Li S, Shiu YT, et al Molecular basis of mechanical modulation of endothelial cell migration. Front Biosci. 2005; 10: 1985-2000.
33. Peng X, Ueda H, Zhou H, et al Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Res. 2004; 64: 421-30.
34. Lee TY, Gotlieb AI. Early stages of endothelial wound repair: conversion of quiescent to migrating endothelial cells involves tyrosine phosphorylation and actin microfilament reorganization. Cell Tissue Res. 1999; 297: 435-50.
35. Chataigneau T, Zerr M, Chataigneau M, et al Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause. 2004; 11: 255-63.
36. Hermsmeyer RK, Mishra RG, Pavcnik D, et al Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol. 2004; 24: 955-61.
37. Rosano GM, Webb CM, Chierchia S, et al Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000; 36: 2154-9.
38. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA. 2003; 100: 2237-42.
39. Karteris E, Zervou S, Pang Y, et al Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol. 2006; 20: 1519-34.
40. Welter BH, Hansen EL, Saner KJ, et al Membrane-bound progesterone receptor expression in human aortic endothelial cells. J Histochem Cytochem. 2003; 51: 1049-55.
41. Sanchez AM, Flamini MI, Fu XD, et al Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol. 2009; 23: 1193-202.
42. Fu XD, Simoncini T. Extra-nuclear signaling of estrogen receptors. IUBMB Life. 2008; 60: 502-10.
43. Lin VC, Ng EH, Aw SE, et al Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol Endocrinol. 2000; 14: 348-58.
44. Hanks SK, Ryzhova L, Shin NY, et al Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci. 2003; 8: d982-96.
45. Hsia DA, Mitra SK, Hauck CR, et al Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003; 160: 753-67.
46. Aponte M, Jiang W, Lakkis M, et al Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res. 2008; 68: 5839-48.
47. Chan MW, Arora PD, Bozavikov P, et al FAK, PIP5KIgamma and gelsolin cooperatively mediate force-induced expression of alpha-smooth muscle actin. J Cell Sci. 2009; 122: 2769-81.
48. Zhang Q, Wang D, Kundumani-Sridharan V, et al PLD1-dependent PKC{gamma} activation downstream to Src is essential for the development of pathologic retinal neovascularization. Blood. 2010; 116: 1377-85.
49. Nyalendo C, Michaud M, Beaulieu E, et al Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumour cell migration. J Biol Chem. 2007; 282: 15690-9.
50. Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J. 2007; 21: 1730-41.
51. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006; 290: C661-8.
52. Joshi B, Strugnell SS, Goetz JG, et al Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumour cell migration and invasion. Cancer Res. 2008; 68: 8210-20.
53. Sud N, Wiseman DA, Black SM. Caveolin 1 is required for the activation of endothelial nitric oxide synthase in response to 17beta-estradiol. Mol Endocrinol. 2010; 24: 1637-49.
54. Reiske HR, Kao SC, Cary LA, et al Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol Chem. 1999; 274: 12361-6.
55. Del Re DP, Miyamoto S, Brown JH. Focal adhesion kinase as a RhoA-activable signaling scaffold mediating Akt activation and cardiomyocyte protection. J Biol Chem. 2008; 283: 35622-9.
56. Simoncini T, Mannella P, Fornari L, et al Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004; 145: 5745-56.
57. Adams MR, Kaplan JR, Manuck SB, et al Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990; 10: 1051-7.
58. Adams MR, Register TC, Golden DL, et al Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17: 217-21.